Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The.
Idorsia Pharmaceuticals Ltd: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Spexis AG / Key word: Miscellaneous
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31,.